IGF-1 LR3 Somatotropic-Axis Research Reference

IGF-1 LR3 is a critical tool for researchers investigating the somatotropic axis due to its classification as a long-acting IGF-1 analog, enabling sustained study of IGF-1 receptor signaling and protein synthesis pathways. With 44 PubMed-indexed publications reflecting its utility in various experimental models, and currently 0 ClinicalTrials.gov registered studies, its primary application remains within preclinical and in vitro research settings. This unique analog provides a robust platform for understanding complex growth factor dynamics.

As an engineered variant of insulin-like growth factor-1, Long R3 IGF-1 presents distinct pharmacokinetic and pharmacodynamic properties that make it particularly valuable for sustained experimental investigations into cellular growth, metabolism, and tissue development. Its utility extends across numerous biological systems, offering a consistent and potent means to explore the intricacies of the IGF-1 system without the rapid degradation characteristic of endogenous IGF-1.

Understanding the Somatotropic Axis: A Research Context

The somatotropic axis represents a pivotal neuroendocrine system integral to regulating growth, metabolism, and tissue homeostasis across the lifespan of many organisms. At its core, this intricate cascade begins in the hypothalamus, which secretes growth hormone-releasing hormone (GHRH) to stimulate, and somatostatin to inhibit, the release of growth hormone (GH) from the anterior pituitary gland. GH, a pleiotropic hormone, then travels through the bloodstream to various target tissues, with the liver being a primary site for its most significant endocrine action: stimulating the synthesis and secretion of insulin-like growth factor-1 (IGF-1). This endocrine relay, where GH acts on the liver to produce IGF-1, is a central tenet of the axis, demonstrating a fascinating interplay of systemic and local signaling.

IGF-1, once released into circulation, acts both systemically and locally in an autocrine/paracrine fashion, mediating many of the growth-promoting effects attributed to GH. Its actions are diverse, encompassing cell proliferation, differentiation, and survival, as well as influencing metabolic pathways such as glucose and lipid metabolism. The precise regulation of IGF-1 levels is critical, as both deficiencies and excesses can lead to significant physiological perturbations. IGF-1’s bioavailability and activity are further modulated by a family of six IGF-binding proteins (IGFBPs), which bind IGF-1 with high affinity, extending its half-life, controlling its transport, and regulating its access to target cell receptors. This complex binding protein system adds another layer of sophistication to the somatotropic axis, making it a rich area for detailed scientific investigation into peptide dynamics.

The Somatotropic Axis in Health and Disease Research

Research into the somatotropic axis extends far beyond its role in linear growth, delving into its involvement in muscle development and maintenance, bone density, cardiovascular function, and neurocognitive processes. Disruptions within this axis are implicated in a wide array of pathological conditions, including growth hormone deficiency, acromegaly, Laron syndrome, and certain forms of cachexia or sarcopenia. Furthermore, the axis plays a significant, though complex, role in aging, where a decline in GH and IGF-1 levels is often observed, contributing to age-related changes in body composition and metabolic function. Investigating these perturbations requires precise tools and models to dissect the specific contributions of each component within the axis, and to understand how interventions might modulate its activity.

The study of the somatotropic axis provides a fundamental framework for understanding the physiological effects of compounds like IGF-1 LR3. By examining how exogenous analogs interact with and influence this endogenous system, researchers can gain valuable insights into fundamental biological processes and potential avenues for modulating tissue anabolism, metabolic regulation, and cellular longevity in various preclinical models. The distinct pharmacokinetic profile of IGF-1 LR3, which minimizes the complex interplay with IGFBPs characteristic of endogenous IGF-1, offers a unique research advantage. This allows for more focused investigations into direct IGF-1 receptor signaling pathways without the confounding variables of rapid degradation or extensive protein binding, thus providing a clearer lens through which to observe specific cellular and systemic responses in controlled experimental settings.

IGF-1 LR3: Structural Modifications and Pharmacokinetic Implications for Research

IGF-1 LR3, or Long R3 IGF-1, is a synthetically modified analog of insulin-like growth factor-1 that has been specifically engineered to overcome certain pharmacokinetic limitations inherent to endogenous IGF-1, making it a valuable tool in diverse research applications. The primary structural modification that distinguishes IGF-1 LR3 from its endogenous counterpart is a precise alteration in its amino acid sequence. This involves the substitution of an arginine (R) for a glutamic acid at position 3 (hence ‘R3’) within the polypeptide chain, coupled with the addition of a 13-amino acid extension at the N-terminus. This two-part structural change is not arbitrary; it confers distinct advantages that significantly impact its biological activity and systemic availability within research models.

Molecular Architecture and Receptor Binding

The core sequence of IGF-1 LR3 retains high homology to natural human IGF-1, ensuring its ability to bind effectively to the IGF-1 receptor (IGF-1R) and initiate downstream signaling pathways crucial for growth and metabolism. The specific R3 substitution at position 3, however, plays a critical role in modulating the analog’s interaction with IGF-binding proteins (IGFBPs). Endogenous IGF-1 binds extensively and with high affinity to IGFBPs, particularly IGFBP-3, which acts as a major circulating reservoir and regulator of IGF-1 bioavailability. This strong binding, while physiologically important, can limit the free concentration of IGF-1 available to activate its receptor in research settings, often leading to transient effects.

The most significant pharmacokinetic implication of IGF-1 LR3’s modified structure, particularly the R3 substitution, is its dramatically reduced affinity for IGFBPs. This diminished binding capacity means that a greater proportion of administered IGF-1 LR3 remains in its unbound, biologically active form in circulation for a longer duration compared to endogenous IGF-1. The N-terminal 13-amino acid extension further contributes to this stability and resistance to enzymatic degradation, collectively extending the analog’s effective half-life within research models. This prolonged half-life translates into more sustained receptor activation and cellular responses, allowing researchers to investigate the effects of chronic or sustained IGF-1 signaling with less frequent administration, simplifying experimental protocols and potentially reducing variability in study outcomes. For researchers looking to acquire this specific analog, more details on its purity and formulation can be found on the IGF-1 LR3 product page.

The enhanced stability and reduced IGFBP binding of IGF-1 LR3 offer substantial benefits for specific research designs. Studies requiring a sustained presence of IGF-1 receptor agonists to explore long-term cellular proliferation, tissue remodeling, or metabolic adaptations can leverage IGF-1 LR3’s extended activity. This contrasts sharply with endogenous IGF-1, which would necessitate continuous infusion or very frequent dosing to achieve similar sustained effects, posing practical challenges in many experimental setups. By providing a more stable and consistently available ligand for the IGF-1 receptor, IGF-1 LR3 allows for more robust and interpretable data regarding the direct consequences of prolonged IGF-1 signaling, making it an indispensable tool for investigating intricate biological processes where sustained cellular stimulation is paramount.

Mechanism of Action: IGF-1 Receptor Signaling and Downstream Pathways

The mechanism of action of IGF-1 LR3 largely mirrors that of endogenous IGF-1, primarily through its high-affinity binding to the insulin-like growth factor-1 receptor (IGF-1R). The IGF-1R is a transmembrane receptor tyrosine kinase, a critical component of cellular communication and regulation, belonging to the same receptor superfamily as the insulin receptor. Upon the binding of IGF-1 LR3 to the extracellular domain of the IGF-1R, a series of conformational changes are induced within the receptor. These changes lead to the autophosphorylation of specific tyrosine residues within the intracellular kinase domains of the receptor subunits. This autophosphorylation event serves as the crucial initial step in initiating a complex network of intracellular signaling cascades, ultimately mediating the diverse biological effects attributed to IGF-1.

Key Intracellular Signaling Cascades

Following autophosphorylation, the activated IGF-1R acts as a docking site for various adaptor proteins, most notably the insulin receptor substrate (IRS) proteins (IRS-1, IRS-2, etc.). These IRS proteins become phosphorylated on multiple tyrosine residues, creating binding sites for other signaling molecules containing Src homology 2 (SH2) domains. Two major downstream signaling pathways are predominantly activated by the IGF-1R/IRS complex, each orchestrating distinct cellular responses:

Phosphoinositide 3-Kinase (PI3K)/Akt Pathway: This pathway is paramount for mediating the anabolic, anti-apoptotic, and metabolic effects of IGF-1 LR3. The activated IRS proteins recruit PI3K, which phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 then serves as a membrane-bound secondary messenger, recruiting phosphoinositide-dependent kinase-1 (PDK1) and Akt (also known as Protein Kinase B). Akt subsequently becomes phosphorylated and activated, leading to a cascade of downstream events including the phosphorylation and inactivation of glycogen synthase kinase-3 beta (GSK-3β), activation of mammalian target of rapamycin (mTOR) via inhibition of TSC1/2 complex, and the phosphorylation of forkhead box protein O (FoxO) transcription factors. The activation of mTOR is particularly significant in protein synthesis and cell growth, while FoxO inactivation promotes cell survival and proliferation.
Mitogen-Activated Protein Kinase (MAPK)/ERK Pathway: This pathway is primarily involved in mediating the mitogenic (cell proliferation) and differentiation effects of IGF-1 LR3. Activated IRS proteins can recruit growth factor receptor-bound protein 2 (Grb2), which then forms a complex with Son of Sevenless (Sos), a guanine nucleotide exchange factor. Sos activates Ras, a small GTPase, which in turn activates Raf, MEK, and finally extracellular signal-regulated kinase (ERK). Activated ERK then phosphorylates various cytoplasmic and nuclear targets, including transcription factors, thereby regulating gene expression involved in cell cycle progression, proliferation, and differentiation.

The sustained activation of these pathways by IGF-1 LR3, owing to its prolonged presence in its active form due to reduced IGFBP binding, allows for robust and prolonged cellular responses that are often more challenging to achieve with endogenous IGF-1. This makes IGF-1 LR3 a particularly valuable research tool for investigating chronic effects of IGF-1 signaling in models of tissue repair, regeneration, and metabolic regulation. The comprehensive understanding of these pathways is crucial for researchers delineating the specific roles of IGF-1 LR3 in various physiological and pathological contexts. For a more detailed exploration of these intricate mechanisms, researchers can refer to our dedicated resource on the Mechanism of Action of IGF-1 LR3.

Beyond these primary pathways, IGF-1 LR3 also influences other signaling networks and cellular processes, albeit with varying degrees of contribution depending on the cell type and physiological context. These can include modulation of calcium signaling, activation of specific protein kinase C (PKC) isoforms, and crosstalk with other receptor systems. The concerted action of these pathways culminates in a broad spectrum of cellular outcomes, including enhanced protein synthesis, inhibition of apoptosis, increased nutrient uptake (e.g., glucose), and stimulation of cell cycle progression. The ability of IGF-1 LR3 to consistently engage these multiple pathways makes it an invaluable compound for researchers seeking to dissect the intricate cellular responses driven by IGF-1 receptor activation, providing a powerful means to explore fundamental biological questions related to anabolism, survival, and proliferation in controlled experimental environments.

IGF-1 LR3 in Preclinical Models: Investigating Anabolism and Tissue Remodeling

IGF-1 LR3 has emerged as a significant research tool in preclinical models, primarily due to its potent anabolic and tissue-remodeling properties. Its extended half-life and reduced IGFBP binding, as discussed, allow for more consistent and prolonged activation of IGF-1 receptor signaling, making it highly effective for exploring mechanisms underlying muscle hypertrophy, bone regeneration, and wound healing. The 44 PubMed publications indexed for IGF-1 LR3 underscore a substantial body of research dedicated to characterizing its effects across various biological systems. These studies leverage its distinct pharmacological profile to investigate how sustained IGF-1 receptor activation can drive tissue growth, repair processes, and cellular adaptations in controlled experimental settings.

Research Areas of Focus

One of the most extensively studied applications of IGF-1 LR3 in preclinical research is its role in skeletal muscle anabolism. Researchers utilize models of muscle atrophy, disuse, or injury to investigate how IGF-1 LR3 influences muscle fiber size, protein synthesis rates, and satellite cell proliferation and differentiation. These studies often involve systemic administration or localized delivery in various rodent models, assessing parameters such as muscle mass, fiber cross-sectional area, force production, and molecular markers of protein synthesis (e.g., mTOR pathway activation) and degradation. The sustained anabolic stimulus provided by IGF-1 LR3 offers a powerful means to dissect the precise mechanisms by which IGF-1 signaling promotes muscle growth and recovery, providing insights relevant to conditions involving muscle wasting or impaired regeneration.

Beyond skeletal muscle, IGF-1 LR3 has been a subject of investigation in models of bone formation and repair. The IGF-1 system is known to be a crucial regulator of osteoblast differentiation, proliferation, and activity, as well as influencing osteoclast function. In preclinical models, IGF-1 LR3 has been employed to explore its potential to enhance bone mineral density, accelerate fracture healing, and improve bone tissue architecture. Researchers might use animal models of osteoporosis, bone defects, or delayed union fractures, evaluating outcomes through micro-computed tomography (μCT), histological analysis, and biomechanical testing. The sustained activation of IGF-1R in bone cells, facilitated by IGF-1 LR3, allows for a more thorough examination of its impact on bone matrix deposition and overall skeletal integrity over extended experimental periods.

Furthermore, IGF-1 LR3 is a valuable compound in research investigating tissue repair and regeneration across different physiological contexts. This includes studies on:

Wound Healing: Exploring its capacity to accelerate epidermal and dermal regeneration, enhance collagen synthesis, and promote angiogenesis in models of skin wounds or burns.
Cartilage Repair: Investigating its influence on chondrocyte proliferation, extracellular matrix production, and the overall integrity of articular cartilage in models of osteoarthritis or cartilage injury.
Nervous System Regeneration: Examining its neurotrophic and neuroprotective effects in models of peripheral nerve injury or central nervous system damage, assessing axonal regeneration, myelination, and functional recovery.
Cardiac Remodeling: Studying its potential to influence cardiomyocyte survival, mitigate fibrosis, and modulate cardiac function in models of myocardial ischemia or heart failure.

In each of these areas, the sustained signaling offered by IGF-1 LR3 provides a robust platform for unraveling complex physiological and pathological processes, contributing to a deeper understanding of tissue dynamics and repair mechanisms at both cellular and systemic levels. The ability to maintain consistent IGF-1 receptor activation makes IGF-1 LR3 an indispensable tool for long-term experimental investigations into anabolism and tissue remodeling.

Comparative Analysis: IGF-1 LR3 vs. Endogenous IGF-1 and Other Analogs in Research

In the realm of somatotropic axis research, the choice between endogenous IGF-1, IGF-1 LR3, and other synthetic analogs is dictated by the specific research question, desired pharmacokinetic profile, and the nature of the experimental model. Each form of IGF-1 possesses unique characteristics that render it more or less suitable for particular investigations. Understanding these differences is crucial for designing experiments that yield robust and interpretable data, allowing researchers to precisely modulate IGF-1 signaling in their studies.

Endogenous IGF-1: Biological Precision, Research Challenges

Endogenous IGF-1 is the naturally occurring, single-chain polypeptide hormone produced primarily by the liver in response to growth hormone (GH), but also locally in various tissues. Its biological actions are tightly regulated by a complex interplay with six IGF-binding proteins (IGFBPs). These IGFBPs bind endogenous IGF-1 with high affinity, controlling its bioavailability, transport, and half-life in circulation. While this intricate regulation is essential for physiological homeostasis, it poses significant challenges for research. Administered endogenous IGF-1 in experimental models typically exhibits a very short half-life due to rapid binding to circulating IGFBPs, leading to transient receptor activation. Achieving sustained IGF-1 signaling with the endogenous hormone often necessitates frequent dosing or continuous infusion, which can be logistically demanding and introduce variability in experimental designs.

IGF-1 LR3: Enhanced Pharmacokinetics for Sustained Research Effects

IGF-1 LR3, as previously discussed, is engineered with an R3 substitution and a 13-amino acid N-terminal extension. These structural modifications are specifically designed to reduce its binding affinity to IGFBPs. The primary advantage of IGF-1 LR3 in research is its significantly extended half-life and enhanced bioavailability compared to endogenous IGF-1. This property allows for more sustained activation of the IGF-1 receptor, facilitating investigations into chronic effects of IGF-1 signaling, such as long-term anabolism, tissue remodeling, or metabolic adaptations, with less frequent administration. Researchers can leverage IGF-1 LR3 when they need a consistent and prolonged agonistic effect on the IGF-1 receptor, minimizing the pulsatile nature of endogenous IGF-1 action when administered exogenously and providing a more stable experimental environment.

Other IGF-1 Analogs: Specialized Tools for Specific Questions

Beyond IGF-1 LR3, other synthetic IGF-1 analogs exist, each designed with specific modifications to address particular research needs. One notable example is Des(1-3)IGF-1, often referred to as Des IGF-1. This analog lacks the first three amino acids at the N-terminus of the IGF-1 molecule. This truncated form also exhibits reduced binding to IGFBPs, but it has a different profile compared to IGF-1 LR3. Des IGF-1 is often considered to have a more potent short-term anabolic effect, particularly when applied locally, due to its ability to rapidly dissociate from any bound IGFBPs and quickly access the IGF-1 receptor. Researchers might choose Des IGF-1 for studies requiring acute, localized IGF-1 action, such as in certain wound healing models or studies focusing on immediate cellular responses, where a burst of activity rather than sustained signaling is desired.

The selection of an IGF-1 analog for research is therefore a critical decision influencing experimental outcomes. The table below summarizes key comparative features to guide researchers in their selection, emphasizing that each analog offers distinct advantages depending on the scientific objectives, whether they involve systemic, sustained effects or localized, acute responses.

Characteristic	Endogenous IGF-1	IGF-1 LR3	Des(1-3)IGF-1
Structural Modification	None (natural form)	Arg at pos 3, 13-AA N-terminal extension	Deletion of Frequently Asked Questions What is IGF-1 LR3 and how does it differ from endogenous IGF-1 for research purposes? IGF-1 LR3, or Long R3 IGF-1, is a synthetic analog of insulin-like growth factor-1 (IGF-1) that has been structurally modified to enhance its stability and extend its half-life in biological systems. For research, its primary differentiation from endogenous IGF-1 lies in its significantly reduced binding affinity to insulin-like growth factor-binding proteins (IGFBPs). Endogenous IGF-1 is tightly regulated by IGFBPs, which sequester a large proportion of the growth factor, limiting its bioavailability and activity. The modifications in IGF-1 LR3, specifically the substitution of arginine for glutamic acid at position 3 (R3) and the addition of a 13-amino acid extension at the N-terminus, largely prevent its interaction with IGFBPs. This results in a higher proportion of free, biologically active IGF-1 LR3 that can bind to the IGF-1 receptor for a longer duration, offering researchers a sustained and potent signaling stimulus for their experimental models. This prolonged action is particularly advantageous for studies requiring sustained growth factor exposure without frequent re-administration, allowing for clearer observation of long-term cellular and physiological effects within the somatotropic axis. How does IGF-1 LR3 interact with the IGF-1 receptor in research models? IGF-1 LR3 interacts with the IGF-1 receptor (IGF-1R) with high affinity, similar to endogenous IGF-1. Upon binding, it induces receptor autophosphorylation and initiates a cascade of intracellular signaling events. The IGF-1R is a tyrosine kinase receptor, and its activation primarily triggers two major downstream pathways: the phosphoinositide 3-kinase (PI3K)/Akt pathway and the mitogen-activated protein kinase (MAPK)/ERK pathway. The PI3K/Akt pathway is critical for mediating many of IGF-1’s anabolic and anti-apoptotic effects, promoting protein synthesis, cell survival, and glucose metabolism. The MAPK/ERK pathway is predominantly involved in cell proliferation and differentiation. In research models, IGF-1 LR3’s sustained presence and reduced IGFBP binding allow for prolonged and robust activation of these pathways, facilitating the study of their roles in various cellular processes, including muscle hypertrophy, tissue regeneration, and metabolic regulation. Researchers can utilize IGF-1 LR3 to precisely modulate IGF-1R signaling and investigate the specific contributions of these pathways to observed biological outcomes in vitro and in vivo. Why is IGF-1 LR3 considered a valuable tool for studying the somatotropic axis? IGF-1 LR3 is considered a valuable tool for studying the somatotropic axis primarily due to its extended half-life and enhanced bioavailability compared to native IGF-1. The somatotropic axis, comprising the hypothalamus, pituitary gland, liver, and target tissues, relies on growth hormone (GH) stimulating IGF-1 production, which then mediates many of GH’s growth-promoting and metabolic effects. Native IGF-1’s rapid degradation and tight binding to IGFBPs make it challenging to maintain consistent IGF-1 levels in experimental systems for prolonged observation. IGF-1 LR3 overcomes this limitation, allowing researchers to administer a consistent and sustained IGF-1 stimulus, thereby enabling more stable and reliable investigations into long-term effects on growth, metabolism, and cellular proliferation. This sustained action provides a more controlled experimental environment to dissect the complex interactions within the somatotropic axis, examine chronic cellular adaptations, and explore the downstream physiological consequences of sustained IGF-1 receptor activation in various research models. What are common research applications for IGF-1 LR3 beyond general anabolism? While general anabolism, such as promoting protein synthesis and cellular growth, is a primary research focus for IGF-1 LR3, its applications extend into various specialized areas. Researchers utilize IGF-1 LR3 to investigate its potential roles in tissue regeneration and repair mechanisms, including studies on muscle injury recovery, bone remodeling, and cartilage repair in preclinical models. Its effects on glucose metabolism and insulin sensitivity are also explored, contributing to research on metabolic disorders. Furthermore, IGF-1 LR3 is studied for its neuroprotective properties in various models of neurological conditions, where IGF-1 signaling is implicated in neuronal survival, plasticity, and cognitive function. Research also delves into its anti-catabolic effects, such as in models of muscle wasting or cachexia. In vitro studies often employ IGF-1 LR3 to stimulate cell proliferation, differentiation, and survival in cell culture systems, providing insights into fundamental cellular biology beyond its systemic anabolic effects. Are there any registered clinical trials involving IGF-1 LR3? Based on available data, there are currently 0 registered clinical trials involving IGF-1 LR3 listed on ClinicalTrials.gov. It is important for researchers to understand that IGF-1 LR3 remains strictly a research-use-only compound. Its application is confined to in vitro, preclinical, and laboratory-based studies to investigate biological mechanisms and potential pathways. The absence of registered clinical trials underscores its current status as an experimental agent, not intended for human therapeutic use or evaluation in human subjects. Researchers are reminded to adhere to all institutional guidelines and regulatory frameworks regarding the use of research-grade compounds and to ensure that all experimental work with IGF-1 LR3 is conducted exclusively within a controlled laboratory environment for scientific inquiry. What are the key considerations when designing an experimental study with IGF-1 LR3? When designing an experimental study with IGF-1 LR3, several key considerations are paramount to ensure robust and reproducible results. Firstly, the purity and authenticity of the IGF-1 LR3 compound must be verified, typically through vendor documentation and analytical reports. Dosage determination is crucial; researchers often conduct dose-response studies to establish optimal concentrations for their specific cell lines or animal models, considering the compound’s prolonged action. The route and frequency of administration (for in vivo studies) must be carefully selected to align with the experimental objectives and the compound’s pharmacokinetics. Defined endpoints, such as gene expression, protein levels, cell proliferation, tissue weight, or functional assessments, must be clearly established and validated. Control groups, including vehicle controls and perhaps native IGF-1 comparators, are essential. Ethical considerations for animal models, including housing, welfare, and minimization of discomfort, must strictly comply with institutional animal care and use committee (IACUC) guidelines. Finally, appropriate statistical analyses must be planned to interpret the data accurately. How does the “Long R3” modification in IGF-1 LR3 affect its research utility? The “Long R3” modification, which involves the substitution of arginine for glutamic acid at position 3 and the addition of a 13-amino acid N-terminal extension, profoundly enhances IGF-1 LR3’s utility in research. The most significant impact of this modification is the dramatic reduction in its binding affinity to insulin-like growth factor-binding proteins (IGFBPs). In physiological systems, IGFBPs bind to endogenous IGF-1, acting as carrier proteins that regulate its bioavailability and half-life. By largely evading IGFBP binding, IGF-1 LR3 remains in its “free” or unbound form for a significantly longer duration. This translates to increased bioavailability and a prolonged half-life in experimental models, allowing for sustained activation of the IGF-1 receptor. For researchers, this means that a single administration can provide a more consistent and prolonged growth factor stimulus, which is invaluable for studying chronic effects, cellular adaptations, and long-term signaling pathways without the confounding variable of rapid degradation or sequestration inherent to native IGF-1. What precautions should researchers take when handling IGF-1 LR3? When handling IGF-1 LR3, researchers should observe standard laboratory safety precautions consistent with handling any research-grade peptide or biological reagent. This includes wearing appropriate personal protective equipment (PPE), such as laboratory coats, gloves, and eye protection, to prevent direct skin contact or accidental ingestion. Work should be conducted in a well-ventilated area, preferably under a fume hood or in a biological safety cabinet, especially when reconstituting lyophilized powder to avoid inhalation of fine particles. Accurate weighing and dilution are critical for experimental consistency and safety. Proper storage conditions, typically at low temperatures (-20°C or -80°C) as a lyophilized powder or in aliquoted solutions, are essential to maintain the compound’s stability and activity. Researchers must also adhere to institutional guidelines for the safe disposal of chemical and biological waste. Critically, strict adherence to the research-use-only nature of IGF-1 LR3 is paramount, ensuring it is never used or implied for human consumption, therapeutic application, or any purpose outside of controlled scientific investigation. Scientific References PubMed: IGF-1 LR3 ClinicalTrials.gov: IGF-1 LR3 All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use. IGF-1 LR3 in Anabolic-Signaling Research: Research Reference IGF-1 LR3 in Igf-Signaling Research: Research Reference Royal Peptide Labs is a Michigan-based supplier of high-purity research peptides. We focus on consistent quality, competitive pricing, and fast, reliable order processing for research environments. Email: royalpeptidelabs@gmail.com Address: PO Box 204, 611 N. Axford St., Lake Orion, MI 48361 Merchant DBA Name: Royal Peptide Labs QUICK LINKS Home About Us Products Contact Us Resources Certifications Terms and Conditions Privacy Policy Shipping Policy Refund and Return Policy SOCIAL Disclaimer: All products are sold strictly for research purposes only. Not for human consumption. Copyright © 2026 Royal Peptide Labs Scroll to Top

Characteristic

Endogenous IGF-1

IGF-1 LR3

Des(1-3)IGF-1

Structural Modification

None (natural form)

Arg at pos 3, 13-AA N-terminal extension

Deletion of

Frequently Asked Questions

What is IGF-1 LR3 and how does it differ from endogenous IGF-1 for research purposes?

IGF-1 LR3, or Long R3 IGF-1, is a synthetic analog of insulin-like growth factor-1 (IGF-1) that has been structurally modified to enhance its stability and extend its half-life in biological systems. For research, its primary differentiation from endogenous IGF-1 lies in its significantly reduced binding affinity to insulin-like growth factor-binding proteins (IGFBPs). Endogenous IGF-1 is tightly regulated by IGFBPs, which sequester a large proportion of the growth factor, limiting its bioavailability and activity. The modifications in IGF-1 LR3, specifically the substitution of arginine for glutamic acid at position 3 (R3) and the addition of a 13-amino acid extension at the N-terminus, largely prevent its interaction with IGFBPs. This results in a higher proportion of free, biologically active IGF-1 LR3 that can bind to the IGF-1 receptor for a longer duration, offering researchers a sustained and potent signaling stimulus for their experimental models. This prolonged action is particularly advantageous for studies requiring sustained growth factor exposure without frequent re-administration, allowing for clearer observation of long-term cellular and physiological effects within the somatotropic axis.

How does IGF-1 LR3 interact with the IGF-1 receptor in research models?

IGF-1 LR3 interacts with the IGF-1 receptor (IGF-1R) with high affinity, similar to endogenous IGF-1. Upon binding, it induces receptor autophosphorylation and initiates a cascade of intracellular signaling events. The IGF-1R is a tyrosine kinase receptor, and its activation primarily triggers two major downstream pathways: the phosphoinositide 3-kinase (PI3K)/Akt pathway and the mitogen-activated protein kinase (MAPK)/ERK pathway. The PI3K/Akt pathway is critical for mediating many of IGF-1’s anabolic and anti-apoptotic effects, promoting protein synthesis, cell survival, and glucose metabolism. The MAPK/ERK pathway is predominantly involved in cell proliferation and differentiation. In research models, IGF-1 LR3’s sustained presence and reduced IGFBP binding allow for prolonged and robust activation of these pathways, facilitating the study of their roles in various cellular processes, including muscle hypertrophy, tissue regeneration, and metabolic regulation. Researchers can utilize IGF-1 LR3 to precisely modulate IGF-1R signaling and investigate the specific contributions of these pathways to observed biological outcomes in vitro and in vivo.

Why is IGF-1 LR3 considered a valuable tool for studying the somatotropic axis?

IGF-1 LR3 is considered a valuable tool for studying the somatotropic axis primarily due to its extended half-life and enhanced bioavailability compared to native IGF-1. The somatotropic axis, comprising the hypothalamus, pituitary gland, liver, and target tissues, relies on growth hormone (GH) stimulating IGF-1 production, which then mediates many of GH’s growth-promoting and metabolic effects. Native IGF-1’s rapid degradation and tight binding to IGFBPs make it challenging to maintain consistent IGF-1 levels in experimental systems for prolonged observation. IGF-1 LR3 overcomes this limitation, allowing researchers to administer a consistent and sustained IGF-1 stimulus, thereby enabling more stable and reliable investigations into long-term effects on growth, metabolism, and cellular proliferation. This sustained action provides a more controlled experimental environment to dissect the complex interactions within the somatotropic axis, examine chronic cellular adaptations, and explore the downstream physiological consequences of sustained IGF-1 receptor activation in various research models.

What are common research applications for IGF-1 LR3 beyond general anabolism?

While general anabolism, such as promoting protein synthesis and cellular growth, is a primary research focus for IGF-1 LR3, its applications extend into various specialized areas. Researchers utilize IGF-1 LR3 to investigate its potential roles in tissue regeneration and repair mechanisms, including studies on muscle injury recovery, bone remodeling, and cartilage repair in preclinical models. Its effects on glucose metabolism and insulin sensitivity are also explored, contributing to research on metabolic disorders. Furthermore, IGF-1 LR3 is studied for its neuroprotective properties in various models of neurological conditions, where IGF-1 signaling is implicated in neuronal survival, plasticity, and cognitive function. Research also delves into its anti-catabolic effects, such as in models of muscle wasting or cachexia. In vitro studies often employ IGF-1 LR3 to stimulate cell proliferation, differentiation, and survival in cell culture systems, providing insights into fundamental cellular biology beyond its systemic anabolic effects.

Are there any registered clinical trials involving IGF-1 LR3?

Based on available data, there are currently 0 registered clinical trials involving IGF-1 LR3 listed on ClinicalTrials.gov. It is important for researchers to understand that IGF-1 LR3 remains strictly a research-use-only compound. Its application is confined to in vitro, preclinical, and laboratory-based studies to investigate biological mechanisms and potential pathways. The absence of registered clinical trials underscores its current status as an experimental agent, not intended for human therapeutic use or evaluation in human subjects. Researchers are reminded to adhere to all institutional guidelines and regulatory frameworks regarding the use of research-grade compounds and to ensure that all experimental work with IGF-1 LR3 is conducted exclusively within a controlled laboratory environment for scientific inquiry.

What are the key considerations when designing an experimental study with IGF-1 LR3?

When designing an experimental study with IGF-1 LR3, several key considerations are paramount to ensure robust and reproducible results. Firstly, the purity and authenticity of the IGF-1 LR3 compound must be verified, typically through vendor documentation and analytical reports. Dosage determination is crucial; researchers often conduct dose-response studies to establish optimal concentrations for their specific cell lines or animal models, considering the compound’s prolonged action. The route and frequency of administration (for in vivo studies) must be carefully selected to align with the experimental objectives and the compound’s pharmacokinetics. Defined endpoints, such as gene expression, protein levels, cell proliferation, tissue weight, or functional assessments, must be clearly established and validated. Control groups, including vehicle controls and perhaps native IGF-1 comparators, are essential. Ethical considerations for animal models, including housing, welfare, and minimization of discomfort, must strictly comply with institutional animal care and use committee (IACUC) guidelines. Finally, appropriate statistical analyses must be planned to interpret the data accurately.

How does the “Long R3” modification in IGF-1 LR3 affect its research utility?

The “Long R3” modification, which involves the substitution of arginine for glutamic acid at position 3 and the addition of a 13-amino acid N-terminal extension, profoundly enhances IGF-1 LR3’s utility in research. The most significant impact of this modification is the dramatic reduction in its binding affinity to insulin-like growth factor-binding proteins (IGFBPs). In physiological systems, IGFBPs bind to endogenous IGF-1, acting as carrier proteins that regulate its bioavailability and half-life. By largely evading IGFBP binding, IGF-1 LR3 remains in its “free” or unbound form for a significantly longer duration. This translates to increased bioavailability and a prolonged half-life in experimental models, allowing for sustained activation of the IGF-1 receptor. For researchers, this means that a single administration can provide a more consistent and prolonged growth factor stimulus, which is invaluable for studying chronic effects, cellular adaptations, and long-term signaling pathways without the confounding variable of rapid degradation or sequestration inherent to native IGF-1.

What precautions should researchers take when handling IGF-1 LR3?

When handling IGF-1 LR3, researchers should observe standard laboratory safety precautions consistent with handling any research-grade peptide or biological reagent. This includes wearing appropriate personal protective equipment (PPE), such as laboratory coats, gloves, and eye protection, to prevent direct skin contact or accidental ingestion. Work should be conducted in a well-ventilated area, preferably under a fume hood or in a biological safety cabinet, especially when reconstituting lyophilized powder to avoid inhalation of fine particles. Accurate weighing and dilution are critical for experimental consistency and safety. Proper storage conditions, typically at low temperatures (-20°C or -80°C) as a lyophilized powder or in aliquoted solutions, are essential to maintain the compound’s stability and activity. Researchers must also adhere to institutional guidelines for the safe disposal of chemical and biological waste. Critically, strict adherence to the research-use-only nature of IGF-1 LR3 is paramount, ensuring it is never used or implied for human consumption, therapeutic application, or any purpose outside of controlled scientific investigation.

Scientific References

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.